JD.Com Inc vs Viatris Inc — how do they compare? JD.Com Inc trades at $27.14 (market cap $36.62B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: JD.Com Inc is the larger of the two by market cap, and JD.Com Inc pays the higher dividend (3.72%). Which is the better fit depends on your goals — on Pluang, investors hold JD.Com Inc for 85 Days and Viatris Inc for 57 Days on average.
| JD | VTRS | |
|---|---|---|
Market Cap | $36.62B | $20.03B |
Volume | 6,571,477 | 14,109,977 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.53 | $18.27 |
52-Week Low | $25.19 | $9.74 |
Typical Hold Time | 85 Days | 57 Days |
Enterprise Value | $19.26B | $32.15B |
Dividend Yield | 3.72% | 2.75% |
Signals from Pluang's Aura AI — not financial advice
JD.com trades at $27.17, up 0.5% on the day, with strong analyst support (69.6% buy ratings) and a consensus price target of $35.86 suggesting 32% upside. Recent quarterly earnings have consistently beaten expectations, though revenue growth has slowed to 0.3% year-over-year for 2026. The stock appears fundamentally undervalued with a P/E of 17.9 and P/S of 0.2, while technical indicators show a mixed but slightly bullish bias with key support at $27.
JD offers significant valuation upside potential given its low multiples and strong cash position, but faces headwinds from slowing revenue growth and regulatory scrutiny of its European expansion. The company's robust balance sheet with $234 billion cash provides stability, though competitive pressures in Chinese e-commerce and macroeconomic concerns remain key risks for investors.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →